To evaluate plecanatide for treating constipation.
Irritable Bowel Syndrome-Constipation (IBS-C)
If patient is eligible, medication is open-label.
Individuals who have IBS-C but no IBS-D or IBS-M and do not have an obstruction in their digestive track. Also, cannot have a bilirubin or any other laboratory value >3X ULN.
To evaluate obeticholic acid (OCA) for treating nonalcoholic steatohepatitis fatty liver disease
Eligible patients may receive medication or placebo. Lengthy study (1-year treatment and up to 5 years follow-up).
Patients with fatty liver. (Fatty liver changes seen on CTs). No alcohol abuse. Will need CBC, CMP, BMI and DM to evaluate qualification for study.